New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presen...(s of 0 for rectal bleeding and stool fre...),Health

Date:10/15/2007

s of 0 for rectal bleeding and stool frequency, a combined Physician's Global Assessment and sigmoidoscopy score of less than or equal to 1, with a sigmoidoscopy score reduction of greater than or equal to 1 point from baseline and no mucosal friability. Of the 451 patients included in the analysis, this post-hoc analysis showed that 70.5 percent (117/166) of patients with mild ulcerative colitis and 64.2 percent (183/285) of patients with moderate ulcerative colitis were in remission at 12 months.

LIALDA for Maintenance of Remission of Mild-to-Moderate Ulcerative Colitis Irrespective of Patient's Previous Relapse History

Poster Presentation: Sunday, October 14, 2007, Exhibit Hall B, #283

A different post-hoc analysis of secondary endpoints from study 303 was done to understand the effect of relapse history in patients with mild-to-moderate ulcerative colitis on the efficacy of maintenance therapy. A total of 438 patients with complete relapse records at baseline (prior to enrolling in either parent study 301 or 302) were analyzed in this post-hoc analysis with LIALDA 2.4g/day. Of patients who previously experienced <3 relapses in the two years prior to parent study baseline, the analysis showed 70.1 percent (192/274) achieved remission at 12 months. In comparison, 59.8 percent (98/164) of patients who previously experienced greater than or equal to 3 relapses in the two years prior to parent study baseline achieved remission at 12 months.

LIALDA for Maintenance in Both Left-Sided and Extensive Ulcerative Colitis

Poster Presentation: Tuesday, October 16, 2007, Exhibit Hall B, #949

Another post-hoc analysis of secondary endpoints from study 303 assessed the efficacy of LIALDA 2.4g/day (given once daily or in two divided doses) for the maintenance of remission in ulcerative colitis patients with a medical history of either a left-sided or extensive condition. Of the 450 patients with known extent of disease included in the analysis,
'/>"/>

SOURCE Shire plc Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
2. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Data Analyses Outline Efficacy and Safety of Mircera for the Treatment of Renal Anemia Associated With Chronic Kidney Disease
5. Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
6. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
7. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
8. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
9. 8-Year Long-term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission with Bexxar
10. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
11. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates